Eli Lilly posted $12.73 billion in revenue in the first quarter, a 45% jump from the prior year, matching the percentage ...

Eli Lilly & Co. cut its earnings outlook on research charges and maintained its full-year sales guidance as its blockbuster ...

LONDON - The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for ...

LONDON (Reuters) -The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in ...

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Novo Nordisk said that it will begin offering its popular weight loss drug Wegovy through telehealth companies Hims & Hers, Ro and LifeMD to expand patient access, now that the medication is no longer ...

Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy ® (semaglutide).